PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

BOSTON, January 06, 2025 -- ( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker ...

PureTech Systems Inc., a pioneer in geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the launch of its Rapid Deploy Autonomous Perimeter ...

The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...

PHOENIX, Dec. 12, 2024 /PRNewswire/ -- PureTech Systems Inc., a leader in geospatial AI-boosted video analytics for wide-area perimeter and border security, is excited to announce the launch of ...

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...